AMGEN INC - FORM 10-K - EX-32 - SECTION 1350 CERTIFICATIONS - February 12, 2020

Attached files

file filename
EX-2.3 - AMENDMENT TO NO. 2 TO THE ASSET PURCHASE AGREEMENT BETWEEN AMGEN AND CELGENE - AMGEN INCa23amendmentno2toapa.htm
10-K - 10-K - AMGEN INCamgn-12312019x10kq42019.htm
EX-31 - RULE 13A-14(A) CERTIFICATIONS - AMGEN INCamgn-ex3120191231xq4.htm
EX-21 - SUBSIDIARIES OF THE COMPANY - AMGEN INCexhibit21significantsu.htm
EX-10.42 - GUARANTEE AGREEMENT - AMGEN INCa1042guaranteeagreement.htm
EX-10.41 - COLLABORATION AGREEMENT - AMGEN INCa1041bridgecollaborati.htm
EX-10.21 - SECOND AMENDMENT TO NONQUALIFIED DEFERRED COMPENSATION PLAN - AMGEN INCa1021-secondamendmentt.htm
EX-10.14 - SECOND AMENDMENT TO SUPPLEMENTAL RETIREMENT PLAN - AMGEN INCa1014-secondamendmento.htm
EX-10.11 - FORM OF CASH-SETTLED RESTRICTED STOCK UNIT AGREEMENT - AMGEN INCa1011-amgenxdirectorca.htm
EX-10.10 - FORM OF RESTRICTED STOCK UNIT AGREEMENT - AMGEN INCa1010-amgenxdirectorrs.htm
EX-10.8 - DIRECTOR EQUITY INCENTIVE PROGRAM - AMGEN INCa108-finalamendeddirec.htm
EX-10.7 - FORM OF PERFORMANCE UNIT AGREEMENT - AMGEN INCa107performanceunitagr.htm
EX-10.5 - FORM OF RESTRICTED STOCK UNIT AGREEMENT - AMGEN INCa105restrictedstockuni.htm
EX-10.4 - FORM OF GRANT OF STOCK OPTION AGREEMENT - AMGEN INCa104grantofstockoption.htm
EX-4.29 - DESCRIPTION OF SECURITIES - AMGEN INCa429descriptionofsecur.htm
EX-2.4 - LETTER AGREEMENT - TREATMENT OF CERTAIN PRODUCT INVENTORY - AMGEN INCa24letteragreementv3.htm
Exhibit 32

Certification of Chief Executive Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:
(i)
the accompanying Annual Report on Form 10-K of the Company for the period ended December 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii)
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 12, 2020
/s/ ROBERT A. BRADWAY
 
Robert A. Bradway
 
Chairman of the Board,
 
Chief Executive Officer and President
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

1

Certification of Chief Financial Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:
(i)
the accompanying Annual Report on Form 10-K of the Company for the period ended December 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii)
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 12, 2020
/s/ PETER H. GRIFFITH
 
Peter H. Griffith
 
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

2

Stock widget

Investing forum

AMGEN INC Reports